Skip to main content
All lobbying filings

WILLIAMS AND JENSEN, PLLC

Lobbying for BEONE MEDICINES ( FORMERLY KNOWN AS BEIGENE USA, INC.) · Healthcare/Pharmaceuticals

 Filing 3rd Quarter - Amendment
Reporting period
3rd Quarter 2025
July 1 - Sep 30 · Posted Oct 20, 2025
Income
$80,000.00
What the client paid this registrant for the period.
Client based in
Massachusetts

Official filing document

 Lobbyists on this filing 1
  • JEANNE HAGGERTY New on this filing
    Previously held: Legislative Correspondent Senator Chuck Grassley and Senate Aging Committee (shared staff), Legislative Aide Senate Finance Committee, Health Policy Coordinator Health Subcommittee Energy and Commerce, Professional Staff Member

A "covered position" is a government job the lobbyist held in the 20 years before registering, which the law requires them to name. See the revolving door for former members of Congress across all filings.

 Government bodies contacted 3
  • Centers For Medicare and Medicaid Services (CMS)
  • HOUSE OF REPRESENTATIVES
  • SENATE

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when.

 Bills named in this filing 2
 Lobbying activity 5
Medicare/Medicaid

Issues related to drug pricing and reimbursement for prescription drugs related to Inflation Reduction Act of 2022 (PL 117-169), Subtitle B (Part B and D drug pricing), access and coverage, most-favored nation drug pricing policies, ORPHAN Cures Act implementation.

Manufacturing

Monitoring efforts to onshore and build US pharmaceutical manufacturing capacity.

Pharmacy

H.R.830/S. 864, HELP Copays Act of 2023; Pharmacy Benefit Manager transparency, including Lower Costs, More Transparency Act.

Health Issues

Monitor progress of next Prescription Drug User Fee Reauthorization, issues relating to US and international manufacturing, oncology issues, FDA reorganization and programs, 340B, monitoring efforts around direct-to-consumer policies.

Trade (domestic/foreign)

Monitoring 232 investigations, monitoring tariffs, most favored nation drug pricing policies, pharmaceutical IP issues.

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.

Report a problem